Etrumadenant
- Generic Name
- Etrumadenant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N8O
- CAS Number
- 2239273-34-6
- Unique Ingredient Identifier
- W0ZE0NT8IF
- Associated Conditions
- -
- Associated Therapies
- -
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04381832
- Locations
- πΊπΈ
Florida Cancer Specialists East, West Palm Beach, Florida, United States
πΊπΈThe Oncology Institute of Hope & Innovation, Cerritos, California, United States
πΊπΈThe University of California, Los Angeles, Encino, California, United States
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04262856
- Locations
- πΊπΈ
Allegheny General Hospital (AGH)-Alleghney Singer Research Institute, Pittsburgh, Pennsylvania, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈInnovative Clinical Research Institute (ICRI), Whittier, California, United States
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT03846310
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
π°π·Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
π°π·Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- David Oh
- Target Recruit Count
- 68
- Registration Number
- NCT03821246
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
πΊπΈAlvin J. Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03720678
- Locations
- πΊπΈ
Carolina BioOncology Institute, Huntersville, North Carolina, United States
πΊπΈArizona Clinical Research Center, Tucson, Arizona, United States
π¦πΊPeninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03719326
- Locations
- π¦πΊ
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
πΊπΈVirginia Cancer Specialists, PC, Fairfax, Virginia, United States
πΊπΈTexas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03629756
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
π¦πΊCabrini Health Limited, Malvern, Australia
πΊπΈScottsdale Healthcare Hospitals dba HonorHealth, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.